{"id":62068,"date":"2025-10-22T07:04:37","date_gmt":"2025-10-22T05:04:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/"},"modified":"2025-10-22T07:04:37","modified_gmt":"2025-10-22T05:04:37","slug":"owlet-announces-pricing-of-public-offering-of-class-a-common-stock","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/","title":{"rendered":"Owlet Announces Pricing of Public Offering of Class A Common Stock"},"content":{"rendered":"
\n

LEHI, Utah–(BUSINESS WIRE)–$owlt<\/a> #babymonitor<\/a>–Owlet, Inc. (\u201cOwlet\u201d or the \u201cCompany\u201d) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company\u2019s Class A common stock (the \u201cOffering\u201d). The shares of Class A common stock are being sold at a public offering price of $7.15 per share, before underwriting discounts and commissions. All of the shares in the Offering are to be sold by the Company. The gross proceeds to Owlet from the Offering are expected to be approximately $30.0 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 629,400 shares of Class A common stock at the public offering price less the underwriting discounts and commissions. The Offering is expected to close on or about October 23, 2025, subject to the satisfaction of customary closing conditions.<\/p>\n

<\/a>
<\/a><\/p>\n

\nOwlet intends to use the net proceeds from the Offering to support continued commercialization and research and development, and for general corporate purposes.<\/p>\n

\nWilliam Blair and TD Cowen are acting as the joint bookrunners for the Offering. Craig-Hallum is acting as co-manager for the Offering.<\/p>\n

\nThe securities described above are being offered by Owlet pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281556) that was previously filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on August 14, 2024. The Offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, copies of which may be obtained, when available, by request from: William Blair & Company, L.L.C., Attn: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687 or by email at: prospectus@williamblair.com<\/a>; or TD Securities (USA) LLC, c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com<\/a>.<\/p>\n

\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n

\nAbout Owlet, Inc.<\/b><\/p>\n

\nOwlet\u2019s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT) offers FDA-cleared medical and consumer pediatric wearables and an integrated HD visual and audio camera that provides real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.<\/p>\n

\nSince 2012, over two million parents worldwide have used Owlet\u2019s platform, contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, without limitation, statements regarding the completion of the Offering, the expected gross proceeds of the Offering, the anticipated use of proceeds from the Offering and the potential exercise by the underwriters of an option to purchase additional shares, are forward-looking statements reflecting the current beliefs and expectations of Owlet\u2019s management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent Owlet\u2019s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, tariffs, the trading price and volatility of Owlet\u2019s Class A common stock, the satisfaction of closing conditions related to the Offering, and risks relating to Owlet\u2019s business, including those identified in the \u201cRisk Factors\u201d section of Owlet\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, in its subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, as well as the preliminary prospectus supplement and accompanying prospectus relating to the Offering. The forward-looking statements included in this press release speak only as of the date of this press release, and Owlet does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
<\/b>pr@owletcare.com<\/a><\/p>\n

\nInvestor Contact:
\n
<\/b>ir@owletcare.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor–Owlet, Inc. (\u201cOwlet\u201d or the \u201cCompany\u201d) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company\u2019s Class A common stock (the \u201cOffering\u201d). The shares of Class A common stock are being sold at a public offering price of $7.15 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62068","6":"format-standard","7":"category-industry"},"yoast_head":"\nOwlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Owlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor–Owlet, Inc. (\u201cOwlet\u201d or the \u201cCompany\u201d) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company\u2019s Class A common stock (the \u201cOffering\u201d). The shares of Class A common stock are being sold at a public offering price of $7.15 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T05:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Owlet Announces Pricing of Public Offering of Class A Common Stock\",\"datePublished\":\"2025-10-22T05:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/\"},\"wordCount\":782,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251021288128\\\/en\\\/2617551\\\/22\\\/Owlet_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/\",\"name\":\"Owlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251021288128\\\/en\\\/2617551\\\/22\\\/Owlet_Logo.jpg\",\"datePublished\":\"2025-10-22T05:04:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251021288128\\\/en\\\/2617551\\\/22\\\/Owlet_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251021288128\\\/en\\\/2617551\\\/22\\\/Owlet_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Owlet Announces Pricing of Public Offering of Class A Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Owlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"Owlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend","og_description":"LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor–Owlet, Inc. (\u201cOwlet\u201d or the \u201cCompany\u201d) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company\u2019s Class A common stock (the \u201cOffering\u201d). The shares of Class A common stock are being sold at a public offering price of $7.15 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-22T05:04:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Owlet Announces Pricing of Public Offering of Class A Common Stock","datePublished":"2025-10-22T05:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/"},"wordCount":782,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/","url":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/","name":"Owlet Announces Pricing of Public Offering of Class A Common Stock - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg","datePublished":"2025-10-22T05:04:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251021288128\/en\/2617551\/22\/Owlet_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/owlet-announces-pricing-of-public-offering-of-class-a-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Owlet Announces Pricing of Public Offering of Class A Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62068"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62068\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}